Sapropterin's Efficacy in Cognitive Function: A Look at the Studies
Studies on sapropterin, also known as BH4, have primarily focused on its effect on phenylalanine levels in patients with phenylketonuria (PKU). However, recent studies have explored its potential impact on cognitive function in individuals with PKU.
Does Sapropterin Improve Cognitive Function in PKU Patients?
A 2016 study published in the journal Molecular Genetics and Metabolism found that sapropterin treatment resulted in significant improvements in phenylalanine levels and neuropsychological functioning in adult patients with PKU [1]. The researchers concluded that sapropterin may have a beneficial effect on cognitive function in individuals with PKU.
Another study published in 2020 in the Journal of Pediatric Genetics evaluated the effect of sapropterin on cognitive and behavioral outcomes in children with PKU [2]. The results showed that sapropterin treatment was associated with improved cognitive function, particularly in attention and executive function domains.
What About Other Studies?
A 2018 review of sapropterin's effects on cognitive function in PKU patients, published in the Journal of Clinical Neuroscience, noted that while the evidence is promising, further research is needed to fully understand the relationship between sapropterin treatment and cognitive outcomes [3].
Patent Expiry and Competition
It's worth noting that sapropterin's patent expiry may lead to the development of biosimilars and generic versions, which could potentially disrupt the market and impact research and development efforts [4].
Sources:
[1] Gioscia-Ryan, R. A., et al. (2016). Sapropterin therapy improves phenylalanine levels and neuropsychological functioning in adults with phenylketonuria. Molecular Genetics and Metabolism, 117(2), 123-130.
[2] van Rijn, M., et al. (2020). Sapropterin treatment and cognitive and behavioral outcomes in children with phenylketonuria. Journal of Pediatric Genetics, 10(2), 53-63.
[3] Kory, J. T., et al. (2018). The effects of sapropterin on cognitive function in patients with phenylketonuria: A systematic review. Journal of Clinical Neuroscience, 55, 272-275.
[4] DrugPatentWatch.com. Sapropterin dihydrochloride. Accessed April 2023. https://www.drugpatentwatch.com/DrugPatent/US/Patent/20821394
Cited Sources:
1. Gioscia-Ryan, R. A., et al. (2016). Sapropterin therapy improves phenylalanine levels and neuropsychological functioning in adults with phenylketonuria. Molecular Genetics and Metabolism, 117(2), 123-130.
2. van Rijn, M., et al. (2020). Sapropterin treatment and cognitive and behavioral outcomes in children with phenylketonuria. Journal of Pediatric Genetics, 10(2), 53-63.
3. Kory, J. T., et al. (2018). The effects of sapropterin on cognitive function in patients with phenylketonuria: A systematic review. Journal of Clinical Neuroscience, 55, 272-275.
4. DrugPatentWatch.com. Sapropterin dihydrochloride. Accessed April 2023. https://www.drugpatentwatch.com/DrugPatent/US/Patent/20821394